About
Chimeric Auto Antibody Receptors
Areas of Focus
Categories
Stem Cell & Cellular TherapyNJ, NY, PA
Team (16)
Anup Marda
Chief Financial Officer
Cabaletta Bio
executive
Arun Das, M.D.
Chief Business Officer
Cabaletta Bio
team_member
Catherine Bollard, M.D.
Independent Director, George Washington University
Cabaletta Bio
board_member
David J
Chief Medical Officer
Cabaletta Bio
executive
Gwendolyn Binder, Ph.D.
President, Science & Technology
Cabaletta Bio
executive
Heather Harte-Hall
Chief Compliance Officer
Cabaletta Bio
team_member
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
7
As Collaborator
0
Total Enrollment
151
By Phase
PHASE1/PHASE2: 5PHASE1: 2
By Status
RECRUITING: 6NOT_YET_RECRUITING: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07006805Lead Sponsor
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
PHASE1/PHASE2Not yet recruiting
12 participants
Started: Aug 31, 2025 · Completed: Oct 31, 2029
NCT06359041Lead Sponsor
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
PHASE1/PHASE2Recruiting
12 participants
Started: Dec 17, 2024 · Completed: Sep 30, 2029
NCT06328777Lead Sponsor
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
PHASE1/PHASE2Recruiting
12 participants
Started: Jul 2, 2024 · Completed: Jul 31, 2029
NCT06121297Lead Sponsor
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
PHASE1/PHASE2Recruiting
12 participants
Started: Feb 16, 2024 · Completed: Dec 31, 2027
NCT06154252Lead Sponsor
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
PHASE1/PHASE2Recruiting
24 participants
Started: Dec 20, 2023 · Completed: Jul 31, 2028
Locations (1)
Headquarters
Philadelphia, PA, United States
Map
Loading map...